Trends and opportunities
The market
China is focused and determined to play a global role in the biotechnology industry. China currently accounts for 16 per cent of the Asia Pacific pharmaceutical market and has over 3500 manufacturers (Source: BMI).
The current market value is estimated at US$8.5 billion with 60 per cent of this generated from sales into the local medical sector.
The government sees biotechnology as a high priority sector, with the nation already a world leader in adult stem cell research. China is also the world’s largest producer of antibiotics, glumatic acid, citric acid, vitamin C and beer.
Some leading Chinese biotechnology firms include:
- SiBono Genetech Ltd. – the first company in the world to receive regulatory approval for gene therapy.
- Jingmei Biotech – produces instrumentation and reagents.
- Beijing Triprime Genetic Engineering – molecular cloning and vaccines.
- Sinovac Biotech – vaccines and diagnostics devices, and has alliances with leading Asian companies. First company in the world to conduct phase I trials on a SARS vaccine. Company has visited Australia and interested in partnering.
China is already committed to bioparks - the major ones include:
- China Beijing Bioengineering and Pharmaceutical Industrial Park
- Shanghai Pudong New Area
- Tiajin Economic-Technological Development Area
- Guangzhou Hi-tech Industrial Development Zone
- Shenzhen Hi-tech Industrial Park
- Hunan Changsa National Economic and Technical Development Zone
|